

Angiotensin II Receptor Blocker Comparison

Various angiotensin receptor II blockers (ARBs) have been periodically shorted. The table below indicates dosing of ARBs based on outcome data. These are estimated equivalencies and patients will need to be monitored following the switch.

| Doses of Angiotensin Receptor Blockers for Various Indications | | | | | | |
|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------------------|---------------------------------------------|---------------------------------------|-----------------------------------------------------------|---------------------------------------------------|
| ARB | HYPERTENSION Approximate Equivalent Daily Dose ^{1,2} | HYPERTENSION Daily Dose Range ^{3,4} | HEART FAILURE Target Dose ^{5,6} | POST-MI Target Dose ^{7,8} | DIABETIC NEPHRO- PATHY Usual Dose ^{3,4} | CV RISK REDUCTION Usual Dose ^{3,4} |
| azilsartan | 40 mg | 20-80 mg | | | | |
| candesartan | 8-16 mg | 4-32 mg | 32 mg daily | 32 mg daily* | | |
| eprosartan | 600 mg | 400-800 mg | | | | |
| irbesartan | 150 mg | 75-300 mg | No difference from placebo | | 300 mg daily | |
| losartan | 50 mg | 25-100 mg | | | 50-100 mg daily | |
| olmesartan | 20 mg | 20-40 mg | | | | |
| telmisartan | 40 mg | 40-80 mg | | | | 80 mg daily |
| valsartan | 80 mg | 80-320 mg | 160 mg BID | 160 mg BID | | |
| *no official indication ARB= angiotensin II receptor blocker; BID = twice daily; CV = cardiovascular; MI= myocardial infarction | | | | | | |

References:

1. Angiotensin II receptor blockers. GlobalRPh. [updated 11 Oct 2017; accessed 02 Jun 2021]. Available from: http://www.globalrph.com/angiotensin_ii_receptor_blockers.htm
2. Government of British Columbia, Ministry of Health. Modernized Reference Drug Program - Angiotensin Receptor Blockers (ARBs). [cited 02 Jun 2021]. Available from: https://www2.gov.bc.ca/assets/gov/health/health-drug-coverage/pharmacare/rdp_decisiontree_arbs.pdf
3. Regier L, Jensen B. ACE Inhibitor (ACEI)/Angiotensin II Receptor Blocker (ARB): Comparison Chart. RxFiles drug comparison charts. Saskatoon, SK: University of Saskatchewan. [updated Apr 2021; accessed 02 Jun 2021]. Available from: <https://www.rxfiles.ca/RxFiles/uploads/documents/members/CHT-HTN-ace-arb.pdf>
4. CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2021 [updated 01 Oct 2014; accessed 02 Jun 2021]. Angiotensin II receptor antagonists (ARBs) [CPhA monograph]. Available from: <http://www.e-cps.ca> or <http://www.myrx.ca>. Also available in paper copy from the publisher.
5. McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021 Apr;37(4):531-546. doi: 10.1016/j.cjca.2021.01.017.

6. Kosar L. Heart failure with reduced ejection fraction (HF-rEF): treatment overview. RxFiles drug comparison charts. Saskatoon, SK: University of Saskatchewan. [updated Apr 2021; accessed 02 Jun 2021]. Available from: <https://www.rxfiles.ca/RxFiles/uploads/documents/members/cht-Heart-Failure.pdf>
7. Jorgenson D, Jensen B, Regier L, et al. Post-myocardial infarction: drug and dosage considerations. RxFiles drug comparison charts. Saskatoon, SK: University of Saskatchewan. [updated Apr 2020; accessed 02 Jun 2021]. Available from: <https://www.rxfiles.ca/RxFiles/uploads/documents/members/cht-Post-MI.pdf>
8. So D. Post-myocardial infarction. In: Therapeutics [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2021 [updated Oct 2020; accessed 02 Jun 2021]. Available from: <http://www.myrx.ca>. Also available in paper copy from the publisher.